Identification of different types of variants and genomic signatures by CGP in solid tumour (FFPE). This is a genotyping EQA only.
Sponsored by
The Comprehensive Genomic Profiling (CGP) [Tissue] pilot EQA scheme is designed to test a laboratory’s ability to detect different types of variants and genomic signatures e.g. SNV, indel, CNV, fusion, TMB by Comprehensive Genomic Profiling (CGP) in solid tumours in the context of precision medicine for cancer e.g. activating/driver mutations and resistance mutations. This is a genotyping only scheme.
02-CGP-27
This EQA is designed for laboratories performing CGP testing.
CNV, NGS, Panel testing, Whole exome sequencing, Whole genome analysis (CNV), Whole genome sequencing
FFPE
English, French, German, Italian, Spanish
No
01/03/2027
Jun-27
June - August 2027 (for exact dates see scheme instructions).
December 2027 - January 2028
Two mock clinical cases with matching samples will be provided.
One FFPE section per case will be provided.
Samples are provided as cut sections (rolled scrolls / curls) only – we cannot provide slide mounted materials.
Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.
Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.
Participants are expected to test the samples according to their routine strategy. For all cases, participants are expected to return results using a data collection form.
Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).
Closes in 112 days
From £310.00
Buying is completed on the EMQN portal and needs a free EMQN account, which takes a few minutes to set up.
Questions about this scheme?
Contact our team
Express your interest in ''.